



广生堂药业
cosunter

广播仁爱·关注民生

2020

2020 08

)

(

.....	1
.....	4
.....	7
.....	14
.....	24
.....	33
.....	37
.....	38
.....	39
.....	40
.....	41
.....	139

		2018
		2020
		2020 1 1 2020 6 30
		2019 1 1 2019 6 30
		2020 6 30

√

	8,714.86	
	7,304,531.58	
	260,393.28	
	2,283,078.44	
	1,484,475.82	
	481,523.99	
	7,890,718.35	--

1

1

□

1

2019



1.2

1

TAF

TAF

25mg

TAF

300mg

TDF

TAF

2019 11

TAF

2020 6

2

sofosbuvir

1

2017 9

2018

34494

36170

2019 8

2020 5

3

(ED)

2019 7

2020 4

4

ED

(ED)

(BPH)

2020 8

2

2015 IPO

1

GST-HG161

c-Met

c-Met

GST-HG161 c-MET 2019 7 9 I c-Met

c-Met GST-HG161 60-450mg 4 9

7

4 SD GST-HG161 600mg

2020 12 31 I 2020 10

GST-HG161 PCT

2

GST-HG151

GST-HG151 NASH

2019 4 GST-HG151

GST-HG151 PCT

3

2015 “ ” GST-HG131/GST-HG121 GST-HG141

2017 AASLD

EASL

GST-HG141 HBV cccDNA cccDNA

2019 11

2020 1 I 2020 5

2020 10 31 Ia Ib GST-HG141 I PI

GST-HG141 HBV PCT

GST-HG131 HBV-RNA HBsAg

2019 12

创新药名称	临床前	临床申请	I期临床	II期临床	III期临床	生产注册申请
新型肝癌靶向药物GST-HG161	→					
非酒精性脂肪肝病及肝纤维化可逆转创新药GST-HG151	→					
乙肝核心蛋白抑制剂GST-HG141	→					
乙肝表面抗原抑制剂GST-HG131	→					
乙肝表面抗原抑制剂GST-HG121	→					

GST-HG161 GST-HG141 GST-HG131

III

1
3,288.58
15.90%
18.98%

2

“ ”

10,060.21
83.68%
58.07%

3

2019 9 24

25

2020 1 17

3,886.55

22.43%

1

(IQVIA)

2017 1.1

2018 1.2

2023

5%

1.5

1,370 2008 240% 2023 (IQVIA) 2018
 1,400-1,700

2

HBV

2017 2015 2.57
 6.2% 1.15 88.7
 2015 9% 8% 170
 2019

2,000 3,000 5% 6% 7,000
 2018 19% 11%

2015 2017 2016 280
 170 80%

3

4

1

	2.73%

	6.51%
	21.35%
	53.34%

4

GMP

100%

100%

5

19.33% 3,480,944.46 11,371,662.81 0.32% 173,237,037.66

533.44%

2019 9 2019 12

588.88% 2020 1 2020

4 101.13%

100%

John Wei-Zhong Mao

GST-HG161 60~450mg 4 600mg

GST-HG141 2020 5 GST-HG131 2020 7

GST-HG121

2020

8

2020 2 14

55,000.00

“ ” “ ”

2020 8 12 2020 8 16 8 21

2020

“ ”

10,000

1,780.43

872.41

2

1

--	--	--	--	--	--

1


8		5		BE BE 2020 8	
9		5		BE 2020 8	
10					
11	GST-HG121				

12 GST-HG131

		201510454570.2	2015-07-29 2035-07-28		
-	HIV-1	201010126780.6	2010-03-04 2030-03-03	5	
		201010126779.3	2010-03-04 2030-03-03		
		201310472328.9	2013-10-11 2033-10-10		
		201310472450.6	2013-10-11 2033-10-10		

12

201310505327.X



	15,193,593.88	7,461,630.24	50.89%	-38.19%	36.63%	-26.89%
	13,280,138.75	5,303,912.20	60.06%	37.79%	106.71%	-13.32%

√

	7,304,531.58	55.70%		
	8,564,078.87	65.30%		
	445,676.88	3.40%		
	375,406.74	2.86%		
	118,213.56	0.90%		

1

	106,392,365.89	11.41%	93,720,021.12	10.46%	0.95%	
	39,479,022.85	4.23%	50,289,922.27	5.61%	-1.38%	
	43,359,513.46	4.65%	35,443,641.90	3.96%	0.69%	
	0	0.00%	0	0.00%	0.00%	/
	66,781,622.32	7.16%	39,865,543.45	4.45%	2.71%	
	215,079,151.55	23.07%	221,113,959.74	24.68%	-1.61%	
	60,659,972.68	6.51%	49,988,118.75	5.58%	0.93%	

2

□

3

1	250,000.00	
2	148,533,137.50	36,439,257.82
3	82.5%	

1

□

2

√

6

1

□

2

□

3

□

1

□

2

□

√

10%

			50,000,000	144,422,003.17	49,655,546.01	72,960,686.58	9,088,058.70	7,459,831.02
			50,000,000	74,277,080.27	23,916,099.48	53,952,501.92	17,296,762.02	17,804,294.37

√

	1,000	235.2	60%
	39.2%	-246,404.57	

1,780.43

49%

872.4

□

2017

2020

“ ”

“ ” “ ” “ ”

2018 11

GST-HG161

GST-HG151

2020 7 6

□

1

2019		43.69%	2020 04 15	2020 04 16	2020041
2020		43.75%	2020 04 17	2020 04 18	2020042
2020		43.68%	2020 04 30	2020 05 01	2020050

2

□

□

√

2015 04 22
2015 4 22
2020 4 21

			6			
				25%		
				40%		
			10		2015 04 22	2018 4 22 2020 4 21
		3		5		
			2020 6 30		2020 02 03	2020 2 3 2020 6 30

□

□

□

□



□

2

□

3

□

4

□

5

□

1

1

□

2

□

3

√

1

44.23

89

B 10

B

2

10%

□

10%

2

□

3

4

√

		GST-HG131	2016 02 25						2,4 00			2016 02 29	2016 008
		GST-HG141	2016 06 02						2,4 00			2016 06 03	2016 051
		GST-HG151	2016 06 02						2,4 00			2016 06 03	2016 051
		GST-HG161	2016 12 19						2,5 50			2016 12 20	2016

													104
		16	2018 02 28						13, 69 8.1 8				2018 03 01 2018 025
			2018 11 28										2018 11 29 2018 121
		GST-HG121	2019 03 28										2019 03 29 2019 015
			2020 04 14						70 0				2020 04 15 2020 039

1

	COD		1		46.825mg/L	100mg/L	0.2992t	4.56t	
			1		4.672mg/L	20mg/L	0.0267t	0.91t	
			1		14.21mg/L	30mg/L	0.1621t	1.37t	
			1		0mg/L	0.3mg/L	0	/	
			2		3.23mg/m ³	80mg/m ³	0.124t	16.8t	

			2		4mg/m ³	200mg/ m ³	0.0075t	0.256t	
			2		113mg/m ³	250mg/ m ³	0.0834t	0.32t	
			2		6.3mg/m ³	30mg/m ³	0.0049t	0.0384 t	

2020 6

“ ”

2012

2012 2 1

72012001 2016

2016 11 18

350926-2016-04-L 2019

2019 11 05

2

3

2020 3 25

Mao John Wei-Zhong

4

A
2020 4 1 2020 4 17

2020

A
55,000.00
”

A

28,000,000 28,000,000

“ ” “

A 2020 7 6

2020 8
2020 8 21

5

6

2020063

7

2020 6 30

525

5%

2020 7

92.5%

√

1

2020

A “ ”
2020052

1

	27,608,100	19.72%	0	0	0	-1,619,426	-1,619,426	25,988,674	18.56%
1	0	0.00%	0	0	0	0	0	0	0.00%
2	0	0.00%	0	0	0	0	0	0	0.00%
3	27,608,100	19.72%	0	0	0	-1,619,426	-1,619,426	25,988,674	18.56%
	0	0.00%	0	0	0	0		0	0.00%
	27,608,100	19.72%	0	0	0	-1,619,426	-1,619,426	25,988,674	18.56%
4	0	0.00%	0	0	0	0	0	0	0.00%
	0	0.00%	0	0	0	0	0	0	0.00%
	0	0.00%	0	0	0	0	0	0	0.00%
	112,391,900	80.28%	0	0	0	1,619,426	1,619,426	114,011,326	81.44%
1	112,391,900	80.28%	0	0	0	1,619,426	1,619,426	114,011,326	81.44%
2	0	0.00%	0	0	0	0	0	0	0.00%
3	0	0.00%	0	0	0	0	0	0	0.00%
4	0	0.00%	0	0	0	0	0	0	0.00%
	140,000,000	100.00%	0	0	0	0	0	140,000,000	100.00%

√

2019

□

□

□

□

□

		5.36%	7,500,000	0	5,625,000	1,875,000		
19	E1	5.14%	7,200,000	0	0	7,200,000		
19	E2	3.93%	5,500,000	0	0	5,500,000		
		1.31%	1,833,561	539,174	0	1,833,561		
		0.71%	1,000,000	0	0	1,000,000		
		0.70%	980,000	931,700	0	980,000		
10	3							
		1	19 E1					
			19 E2	2019				
		2						
10								
			22,368,651			22,368,651		
			10,125,000			10,125,000		
19	E1				7,200,000			
19	E2				5,500,000			
			3,403,717			3,403,717		
			3,384,175			3,384,175		
			1,875,000			1,875,000		
			1,833,561			1,833,561		
			1,000,000			1,000,000		
			980,000			980,000		
10	10	10	1 19 E1					

		19	E2	2019
			2	
10				16,368,651
	4			6,000,000

10

10

□

10

10

□

□

□

□

□

2019

√

			2020 03 25	/
John Wei-Zhong Mao			2020 03 25	/
			2020 03 25	/
			2020 03 25	/
			2020 03 25	/
			2020 03 25	
			2020 03 25	
			2020 03 25	

□

1

2020 06 30

	2020 6 30	2019 12 31
	106,392,365.89	93,720,021.12
	4,698,485.18	10,070,393.83
	39,479,022.85	50,289,922.27
	1,883,134.02	3,502,845.79
	2,200,328.48	1,161,941.70
	43,359,513.46	35,443,641.90

	3,562,632.34	3,792,123.13
	201,575,482.22	197,980,889.74
	66,781,622.32	39,865,543.45
	215,079,151.55	221,113,959.74
	60,659,972.68	49,988,118.75
	138,789,745.35	130,311,303.43
	51,497,512.73	51,880,941.32
	58,968,390.42	58,968,390.42
	3,651,305.01	1,667,555.92
	16,900,891.30	16,834,612.73
	118,430,161.88	127,267,035.49
	730,758,753.24	697,897,461.25
	932,334,235.46	895,878,350.99
	133,164,739.73	100,122,731.03

	37,015,852.84	31,030,356.66
		9,459,681.79
	4,753,205.82	
	8,501,131.01	11,030,602.04
	3,333,547.11	7,299,138.81
	45,389,909.93	61,922,694.72
	14,506,811.11	11,687,547.78
	617,916.76	
	247,283,114.31	232,552,752.83
	00	34,800,000.00

	140,000,000.00	140,000,000.00
	179,372,735.07	178,270,643.57
	44,036,242.10	44,036,242.10
	214,640,376.12	203,268,713.31
	578,049,353.29	565,575,598.98
	11,266,387.98	10,151,950.32
	589,315,741.27	575,727,549.30
	932,334,235.46	895,878,350.99

2

	2020 6 30	2019 12 31
	79,321,854.06	65,684,653.46
	4,044,163.20	9,354,538.13
	15,814,630.35	23,250,140.11
	1,276,358.20	2,214,882.74
	1,813,193.28	713,114.75
	29,353,099.87	21,464,480.79

	1,752,151.00	2,092,572.03
	133,375,449.96	124,774,382.01
	254,959,122.32	225,043,043.45
	143,011,940.43	147,045,293.65
	39,678,677.19	33,532,299.23
	58,785,006.42	57,521,880.97
	51,115,912.73	51,499,341.32
	3,651,305.01	1,646,722.62
	12,728,874.53	12,619,020.10
	117,986,707.24	119,174,390.19
	681,917,545.87	648,081,991.53
	815,292,995.83	772,856,373.54
	100,116,139.45	65,065,975.61
	25,286,541.73	18,717,151.27
		7,788,001.84
	3,834,424.80	
	6,458,498.26	8,908,029.98

	31,694,198.95	46,258,687.41
	14,506,811.11	11,687,547.78
	498,475.22	
	183,660,198.36	159,846,207.87
	46,200,000.00	34,800,000.00
		296,000.00
	11,528,036.77	13,045,542.93
	57,728,036.77	48,141,542.93
	241,388,235.13	207,987,750.80
	140,000,000.00	140,000,000.00
	179,372,735.07	178,270,643.57

	12,857,973.20	11,756,598.14
	375,406.74	620,126.77
	118,213.56	147,510.63
	13,115,166.38	12,229,214.28
	629,065.91	-13,422.66
	12,486,100.47	12,242,636.94
1.	12,486,100.47	15,637,403.45
2.		-3,394,766.51
1.	11,371,662.81	11,335,477.71
2.	1,114,437.66	907,159.23
1.		
2.		
3.		
4.		
5.		
1.		
2.		
3.		
4.		
5.		
6.		
7.		
	12,486,100.47	12,242,636.94
	11,371,662.81	11,335,477.71
	1,114,437.66	907,159.23
	0.0812	0.0810

	0.0812	0.0810
--	--------	--------

4

	2020	2019
	100,064,903.73	142,571,741.80
	42,164,912.90	24,786,226.02
	1,170,870.66	2,148,201.55
	27,637,975.79	71,537,559.19
	14,239,662.59	15,305,579.80
	18,452,113.99	27,091,760.67
	2,822,169.19	1,453,369.06
	3,428,999.70	2,471,308.40
	638,029.85	1,021,969.79
	4,913,229.57	4,384,007.12
	8,564,078.87	-5,054,130.40
	8,564,078.87	1,645,869.60
-	425,032.62	446,244.26
-		
-		-3,108.72
	7,479,539.67	22,057.77
	362,186.66	559,362.09
	10,010.30	46,518.50
	7,831,716.03	534,901.36
	-102,330.43	90,012.51
	7,934,046.46	444,888.85
	7,934,046.46	444,888.85

1.		
2.		
3.		
4.		
5.		
1.		
2.		
3.		
4.		
5.		
6.		
7.		
	7,934,046.46	444,888.85

5

	2020	2019
	204,129,617.88	240,066,453.27

	6,560,036.61	7,032,747.94
	210,689,654.49	247,099,201.21

	95,020,000.00	91,000,000.00
	47,800,000.00	5,800,000.00
	4,161,335.74	3,352,708.53
		33,722,686.20

	00				7				10		31		8.98		
	0.00				1,102,091.50				0.00		11,371,662.81		12,473,754.31	1,114,437.66	13,588,191.97
											11,371,662.81		11,371,662.81	1,114,437.66	12,486,100.47
	0.00				1,102,091.50					0.00			1,102,091.50		1,102,091.50
1					1,102,091.50								1,102,091.50		1,102,091.50
	140,000,000.00				179,372,735.07				44,036,242.10		214,640,376.12		578,049,353.29	11,266,387.98	589,315,741.27

	2019														
	141,211,420.00				214,984,525.63	38,292,986.20			44,029,932.10		191,946,757.72		553,879,649.25	8,308,942.05	562,188,591.30
	141,211,420.00				214,984,525.63	38,292,986.20			44,029,932.10		191,946,757.72		553,879,649.25	8,308,942.05	562,188,591.30
	-1,211,420.00				-36,247,767.29	-38,292,986.20					11,759,474.71		12,593,273.62	907,159.23	13,500,432.85
											11,335,477.71		11,335,477.71	907,159.23	12,242,636.94
	-1,211,420.00				-36,247,767.29	-38,292,986.20					0.00		833,791.11		833,791.11

1					1,102,09 1.50						1,102,091. 50
	140,000 ,000.00				179,372, 735.07			44,036,242 .10	210,495,783. 53		573,904,7 60.70

	2019										
	141,211, 420.00				214,984, 525.63	38,29 2,986. 20			44,029,932 .10	207,095,39 1.76	569,028, 283.29
	141,211, 420.00				214,984, 525.63	38,29 2,986. 20			44,029,932 .10	207,095,39 1.76	569,028, 283.29
	-1,211,42 0.00				-36,247, 767.29	-38,29 2,986. 20			0.00	868,885.85	1,702,68 4.76
										444,888.85	444,888. 85
	-1,211,42 0.00				-36,247, 767.29	-38,29 2,986. 20			0.00	0.00	833,798. 91
1	-1,211,42 0.00				-37,505, 563.20						-38,716,9 83.20
2					1,257,79 5.91	-38,29 2,986. 20					39,550,7 82.11
	0.00				0.00	0.00			0.00	423,997.00	423,997. 00
1									423,997.00		423,997. 00
	140,000, 000.00										

1

2015 4 “ 2015 537 ” 350
 1,750 A
 1,400 2015 4 22 2020 6 30
 14,000.00 913500007297027606
 B 10 B

2

3

2020 8 26

4

1 8

子公司名称	子公司类型	级次	持股比例(%)	表决权比例(%)

“ ”

2 2

名称	变更原因
阿吉安(北京)基因科技有限公司	股权转让
阿吉安(福州)基因医学检验实验室有限公司	系阿吉安(北京)基因科技有限公司全资子公司

“ ”

1

“ ”

15 —

2014

2

12

3.

1

2

1

2

A.

B.

C.

D.

3

4

7

1

1

2

3

2

1

2

3

4

5

8 —

8 —

8

9

10

)

(

)

(

1

1

4

1 2

5

6

12

12

1

2

3

7

1

2

12

10

6.

组合名称	确定组合的依据	计提方法
经销及外包推广模式客户组合	按业务模式分类	矩阵模型分析法
自主推广模式组合	按业务模式分类	矩阵模型分析法

13

14

10

6.

组合名称	确定组合的依据	计提方法
并表范围关联方	款项性质及风险特征	本公司认为该组合的信用风险自初始确认后未显著增加，不会因违约而产生重大损失
信用组合	款项性质及风险特征	按账龄与整个存续期预期信用损失率对照表计提
押金、保证金、员工备用金		本公司认为该组合的信用风险自初始确认后未显著增加，不会因违约而产生重大损失

15

1.

2.

3.

4.

16

)

17

18

19

20

10

6.

21

22

1

1

5

2

2

1

2

3

1

22 —

2

22 —

3

70

22 ——

4

5

22 ——

4

1

2

3

4

1

22 ——

2

1

2

5

1

3

2

5

4

23

24

1

1

1

2

2

1

2

3

4

2

		20	5%	4.75%
		10	5%	9.50%
		5	5%	19.00%
		5	5%	19.00%

1

2

3

3

25

1.

2.

26

1.

1

2

3

2.

3.

3

4.

项目	预计使用寿命	依据
土地使用权	按土地出让年限或尚可使用年限	土地证使用年限
药品生产技术	自取得药品生产批件起5年内摊销	行业惯例
办公软件	5年	行业惯例

化药类别	研发费用资本化政策
化药一类	进入III期临床至取得生产批件之间的费用资本化
化药二类	进入III期临床至取得生产批件之间的费用资本化

2

3

2007 7 10

“

28

”

“

”

中药类别	研发费用资本化政策
中药一类至三类	进入III期临床至取得生产批件之间的费用资本化
中药十类至九类	进入III期临床至取得生产批件之间的费用资本化

31

32

1

类别	摊销年限	依据
自有房屋装修费	10年	预计使用年限
租赁房屋装修费	租期与5年孰短	预计使用年限

33

34

1

2

37

1.

2.

3

4

5

6

1

2

3.

4.

38

39

(1)

(2)

(3)

40

1.

/

2.

1

3.

项目	核算内容
采用总额法核算的政府补助类别	与资产相关和与收益相关
采用净额法核算的政府补助类别	无

41

/

()

1.

1

2

2

2

1

2

43

44

1

√



1

>

2017 7 5

[2017]22

<

14

2020 7

1

2018 1 1

2020 1 1

2020 1 1

2

2020071

14

√

	2019 12 31	2020 01 01	
	93,720,021.12	93,720,021.12	
	10,070,393.83	10,070,393.83	
	50,289,922.27	50,289,922.27	
	3,502,845.79	3,502,845.79	
	1,161,941.70	1,161,941.70	
	35,443,641.90	35,443,641.90	
	3,792,123.13	3,792,123.13	
	197,980,889.74	197,980,889.74	
	39,865,543.45	39,865,543.45	
	221,113,959.74	221,113,959.74	
	49,988,118.75	49,988,118.75	
	130,311,303.43	130,311,303.43	
	51,880,941.32	51,880,941.32	
	58,968,390.42	58,968,390.42	
	1,667,555.92	1,667,555.92	
	16,834,612.73	16,834,612.73	
	127,267,035.49	127,267,035.49	
	697,897,461.25	697,897,461.25	
	895,878,350.99	895,878,350.99	
	100,122,731.03	100,122,731.03	
	31,030,356.66	31,030,356.66	
	9,459,681.79		-9,459,681.79
		8,371,399.81	8,371,399.81
	11,030,602.04	11,030,602.04	
	7,299,138.81	7,299,138.81	
	61,922,694.72	61,922,694.72	
	11,687,547.78	11,687,547.78	

		1,088,281.98	1,088,281.98
	232,552,752.83	232,552,752.83	
	34,800,000.00	34,800,000.00	
	296,000.00	296,000.00	
	49,694,180.71	49,694,180.71	
	2,807,868.15	2,807,868.15	
	87,598,048.86	87,598,048.86	
	320,150,801.69	320,150,801.69	
	140,000,000.00	140,000,000.00	
	178,270,643.57	178,270,643.57	
	44,036,242.10	44,036,242.10	
	203,268,713.31	203,268,713.31	
	565,575,598.98	565,575,598.98	
	10,151,950.32	10,151,950.32	
	575,727,549.30	575,727,549.30	
	895,878,350.99	895,878,350.99	

	2019 12 31	2020 01 01	
	65,684,653.46	65,684,653.46	
	9,354,538.13	9,354,538.13	
	23,250,140.11	23,250,140.11	
	2,214,882.74	2,214,882.74	
	713,114.75	713,114.75	
	21,464,480.79	21,464,480.79	
	2,092,572.03	2,092,572.03	
	124,774,382.01	124,774,382.01	
	225,043,043.45	225,043,043.45	
	147,045,293.65	147,045,293.65	
	33,532,299.23	33,532,299.23	

	57,521,880.97	57,521,880.97	
	51,499,341.32	51,499,341.32	
	1,646,722.62	1,646,722.62	
	12,619,020.10	12,619,020.10	
	119,174,390.19	119,174,390.19	
	648,081,991.53	648,081,991.53	
	772,856,373.54	772,856,373.54	
	65,065,975.61	65,065,975.61	
	18,717,151.27	18,717,151.27	
	7,788,001.84		-7,788,001.84
		6,892,037.03	6,892,037.03
	8,908,029.98	8,908,029.98	
	1,420,813.98	1,420,813.98	
	46,258,687.41	46,258,687.41	
	11,687,547.78	11,687,547.78	
		895,964.81	895,964.81
	159,846,207.87	159,846,207.87	
	34,800,000.00	34,800,000.00	
	296,000.00	296,000.00	
	13,045,542.93	13,045,542.93	
	48,141,542.93	48,141,542.93	
	207,987,750.80	207,987,750.80	
	140,000,000.00	140,000,000.00	
	178,270,643.57	178,270,643.57	
	44,036,242.10	44,036,242.10	
	202,561,737.07	202,561,737.07	
	564,868,622.74	564,868,622.74	
	772,856,373.54	772,856,373.54	

4 2020

√

2020

“ ” “ ” “

”

45

1

		13%
		5% 7%
		15% 25%
		3%
		2%
		0.09%

	15%
	15%
	25%

2

1
 2009 2009 51 2009 2009 12 3 2009
 7 31 2012 7 2012 7 31 2015 9
 2015 9 21 2018 11 8
 2018 -2020 15%
 2 2016 10 20 2016
 GR201632000252 3 2016 -2018 15% 2019 11 7
 2019-2021 15%
 3 2018 99
 2018 1 1 2020 12 31
 75% 175%

3

1

	3,110.50	2,095.50
	106,023,851.37	93,467,925.62
	365,404.02	250,000.00
	106,392,365.89	93,720,021.12

2020 6 30

项目	期末余额	期初余额
应付账款	200000	200000
合计	200000	200000

2

3

4

1

	4,698,485.18	10,070,393.83
	4,698,485.18	10,070,393.83

2020 6 30

□

2

□

3

4

	2,890,885.85	2,590,794.40
	2,890,885.85	2,590,794.40

5

√

1

账龄	期末余额		
	账面余额	坏账准备	计提比例 (%)
1年以内 (含1年)	27,186,457.02	1,324,322.89	5
1至2年	1,703,788.48	255,568.27	15
2至3年	129,002.45	38,700.74	30
3至4年	215,888.00	129,532.80	60
4至5年	144,453.50	130,008.15	90
5年以上	572,477.20	572,477.20	100
合计	29,952,066.65	2,450,610.05	8.18%

2

账龄	期末余额		
	账面余额	坏账准备	计提比例 (%)
1年以内 (含1年)	12,229,390.96	281,300.55	5
1_2	381,373.30		
2_3	5,884.00		
3_4	5,400.01		
4_5			
5	13,610.18		
合计	12,635,658.45	658,092.19	5.21%

1	1	39,415,847.97
1	2	2,085,161.78
2	3	134,886.45
3		951,828.89
3	4	221,288.01
4	5	144,453.50
5		586,087.38
		42,587,725.09

2

	2,383,314.93		32,312.23		2,450,610.05
	1,168,912.57		94,424.09		658,092.19

	3,552,227.50		126,736.32			3,108,702.24
--	--------------	--	------------	--	--	--------------

3

4

	3,148,782.80		7.39%
	3,024,468.24		7.10%
	1,829,809.08		4.30%
	1,658,160.00		3.89%
	1,193,972.86		2.80%
	10,855,192.98		25.48%

5

6

6

□

□

7

1

1	1,675,782.59	88.99%	3,256,005.96	92.95%
1 2	76,868.27	4.08%	220,192.38	6.29%
2 3	60,302.97	3.20%	6,142.35	0.18%
3	70,180.19	3.73%	20,505.10	0.58%
	1,883,134.02	--	3,502,845.79	--

2

单位名称	期末余额	占预付款项总额的比例 (%)	预付款时间	无结算原因
福建新厚洋网络科技有限公司	188,404.36	10.00%	一年内	按合同预付
石家庄龙泽制药股份有限公司	110,000.00	5.84%	一年内	按合同预付
南京天海医药科技有限公司	108,301.89	5.75%	一年内	按合同预付
贵州千叶药品包装有限公司	83,672.60	4.44%	一年内	按合同预付
中石化森美(福建)石油有限公司福州分公司	64,883.22	3.45%	一年内	按合同预付
合计	555,262.07	29.49%		

8

	2,200,328.48	1,161,941.70
	2,200,328.48	1,161,941.70

1

1)

2)

3)

□

2

1)

2)

1

3)

□

3

1)

	243,067.80	75,808.28
	186,396.60	229,267.18
	2,212,038.40	1,175,803.24

2)

	12	()	()	
2020 1 1	11,326.63	2,380.00		13,861.54
2020 1 1	—	—	—	—
	558.87			558.87
	2,710.49			2,710.49
2020 6 30	9,175.01	2,380.00	0.00	11,709.92

□

1 1	1,589,469.04
1 2	18,800.00
2 3	399,739.36
3	204,030.00
3 4	3,000.00
4 5	5,600.00
5	195,430.00
	2,212,038.40

3)

	13,861.54	558.87	2,710.49		11,709.92
	13,861.54	558.87	2,710.49		11,709.92

4)

5)

--	--	--	--

	3,359,261.25		3,359,261.25	7,367.87		497,367.87
	43,522,476.43	162,962.97	43,359,513.46	35,703,887.12	260,245.22	35,443,641.90

2

	6,430.00	4,550.00
	3,562,632.34	3,792,123.13

14

□

15

□

16

1

□

2

3

17

	()									()	
	15,489,784.51			8,724,104.24							24,213,888.75
	24,375,758.94	16,000,000.00		86,379.20							40,462,138.14
		2,352,000.00		-246,404.57							2,105,595.43
	39,865,	18,352,		8,564,0							66,781,62

	543.45	000.00		78.87							2.32
	39,865, 543.45	18,352, 000.00		8,564.0 78.87							66,781.62 2.32

18

19

20

1

□

2

□

3

21

	215,079,151.55	221,113,959.74
	215,079,151.55	221,113,959.74

1

1.	227,226,148.71	83,332,815.10	10,025,633.94	5,091,833.29	325,676,431.04
2.	1,077,471.06	2,134,937.17	286,928.20	328,275.68	3,827,612.11
1	0.00	224,811.51	286,928.20	328,275.68	840,015.39
2	1,077,471.06	1,910,125.66	0.00	0.00	2,987,596.72
3					
3.	0.00	60,523.03	110,106.14	223,250.25	393,879.42
1	0.00	60,523.03	110,106.14	223,250.25	393,879.42
4.	228,303,619.77	85,407,229.24	10,202,456.00	5,196,858.72	329,110,163.73

1.	51,404,276.64	42,258,841.82	7,033,910.89	3,865,441.95	104,562,471.30
2.	5,672,134.20	3,389,731.34	551,841.80	216,289.71	9,829,997.05
1	5,672,134.20	3,389,731.34	551,841.80	216,289.71	9,829,997.05
3.	0.00	46,522.07	102,846.36	212,087.74	361,456.17
1	0.00	46,522.07	102,846.36	212,087.74	361,456.17
4.	57,076,410.84	45,602,051.09	7,482,906.33	3,869,643.92	114,031,012.18
1.	171,227,208.93	39,805,178.15	2,719,549.67	1,327,214.80	215,079,151.55
2.	175,821,872.07	41,073,973.28	2,991,723.05	1,226,391.34	221,113,959.74

2

3

4

5

		3,084,540.78
		4,277,306.32

	33,271,938.78		33,271,938.78	29,850,074.20		29,850,074.20
	19,334,484.85		19,334,484.85	15,208,524.65		15,208,524.65
9	396,954.73		396,954.73	2,489,344.55		2,489,344.55
	1,247,294.87		1,247,294.87	1,247,294.87		1,247,294.87
	252,950.23		252,950.23	252,950.23		252,950.23
	644,990.31		644,990.31	644,990.31		644,990.31
	28,301.89		28,301.89	128,301.89		128,301.89
16	443,333.73		443,333.73			
	399,515.77		399,515.77			
	60,659,972.68		60,659,972.68	49,988,118.75		49,988,118.75

2

		166,638 .05	6,383,6 95.13	1,910,12 5.66		4,640,2 07.52						
		29,850, 074.20	3,421,8 64.58			33,271, 938.78						
		15,208, 524.65	4,833,4 31.26	707,471. 06		19,334, 484.85						
9		2,489,3 44.55	223,14 5.70		2,315, 535.5 2	396,954 .73						
		1,247,2 94.87				1,247,2 94.87						
		252,950 .23				252,950 .23						
		644,990 .31				644,990 .31						

		128,301 .89	270,00 0.00	370,000. 00		28,301. 89						
16			443,33 3.73			443,333 .73						
			399,51 5.77			399,515 .77						
		49,988, 118.75	15,974, 986.17	2,987,59 6.72	2,315, 535.5 2	60,659, 972.68	--	--				--

3

4

23

1

□

2

□

24

□

25

26

1

1.				91,547,054. 28	272,087.38	69,619,862 .55	2,613,267. 36	164,052,27 1.57
2.				9,149,890.0	518,867.92	6,783,460.		16,452,218

				0		56		.48
1				9,149,890.0 0	518,867.92			9,668,757. 92
2						6,783,460. 56		6,783,460. 56
3.								
4.				100,696,94 4.28	790,955.30	76,403,323 .11	2,613,267. 36	180,504,49 0.05
1.				6,346,214.8 7	17,005.46	25,408,626 .92	1,969,120. 89	33,740,968 .14
2.				970,655.29	58,124.16	6,812,751. 33	132,245.78	7,973,776. 56
1				970,655.29	58,124.16	6,812,751. 33	132,245.78	7,973,776. 56
3.								
4.				7,316,870.1 6	75,129.62			

+3	HBV	3	8,803,248.76	454,195.43			9,257,444.19
	0.5mg	1mg	3,404,723.82	41,382.75			3,446,106.57
	100mg	150mg	5,556,302.11	323,558.98		5,879,861.09	
	300mg			2,714,938.22			2,714,938.22
				343,869.85		343,869.85	
				559,729.62		559,729.62	
			51,880,941.32	6,400,031.97		6,783,460.56	51,497,512.73

项目	资本化开始时点	资本化的具体依据	截止期末的研发进度
枸橼酸西地那非原料药及片剂(6类+6类)	2016-10-18	取得人体生物等效性试验批件	已收到CDE下发的补充资料通知,正在开展补充研究
富马酸普诺福韦二吡唑酮片(6类)(HIV)	2016-1-29	取得人体生物等效性试验批件	已收到CDE下发的补充资料通知,正在开展补充研究
索非布韦原料药及片剂(3类+3类)	2016-5-18	取得临床批件	已收到CDE下发的补充资料通知,正在开展补充研究
富马酸普诺福韦艾拉酚胺片	2018-6-7	生物等效性与临床试验备案	已收到CDE下发的补充资料通知,正在开展补充研究
恩替卡韦片	2018-2-14	生物等效性与临床试验备案	已完成补充研究工作并已上交给CDE。目前该品种正在CDE的化药药学一、二部,合规处进行专业审评
拉米夫定片剂一致性评价	2016-5-4	项目立项审批	2020年5月通过仿制药质量与疗效一致性评价
他达拉非原料药及他达拉非片	2020-1-20	生物等效性与临床试验备案	已完成生物等效性临床试验,正在整理申报资料,准备报产

28

1



9		2,315,535.52	77,184.52		2,238,351.00
	1,667,555.92	2,315,535.52	331,786.43		3,651,305.01

30 /

1

	3,304,846.48	710,178.34	3,826,334.26	788,319.25
	67,328,844.75	11,553,681.79	54,084,907.39	9,325,436.81
	16,616,821.80	2,492,523.28	27,263,704.03	4,348,722.88
	11,528,036.77	1,729,205.52	13,045,542.93	1,956,831.44
	1,969,763.25	295,464.49	1,969,763.25	295,464.49
	798,919.22	119,837.88	798,919.22	119,837.86
	101,547,232.27	16,900,891.30	100,989,171.08	16,834,612.73

2

0000 00

	11,569.31	255,119.24
	11,569.31	255,119.24

5

2020 6 30

31

--	--	--

Ní

1

	17,821,497.98	13,287,797.91
	4,979,703.00	6,828,055.74
	14,214,651.86	10,914,503.01
	37,015,852.84	31,030,356.66

2

1

37

1

2

1

4,753,205.82	8,371,399.81
4,753,205.82	

3		805,157.37	805,157.37	
	0.00	727,794.23	727,794.23	
	0.00	14,131.15	14,131.15	
	0.00	63,231.99	63,231.99	
4		830,967.40	830,967.40	
5	1,198,710.52	465,593.72	417,673.85	1,246,630.39
	10,763,700.04	38,510,763.69	40,773,332.72	8,501,131.01

3

1		342,712.20	342,712.20	
2		11,518.80	11,518.80	
		354,231.00	354,231.00	

40

		1,713,848.17	2,513,512.54
		656,412.59	3,544,330.51
		134,637.49	357,267.98
		136,557.17	160,862.07
		356,421.10	355,977.12
		204,791.73	204,791.73
		108,998.63	125,762.37
		14,467.93	19,844.72
		7,412.30	16,789.77
		3,333,547.11	7,299,138.81

41

		45,389,909.93	61,922,694.72
		45,389,909.93	61,922,694.72

1

2

3

1)

	24,154,111.92	29,311,896.26
	20,598,006.52	31,624,439.55
	637,791.49	986,358.91
	45,389,909.93	61,922,694.72

2) 1

2020 6 30

42

43

	14,400,000.00	11,600,000.00
	106,811.11	87,547.78
	14,506,811.11	11,687,547.78

44

	617,916.76	1,088,281.98
	617,916.76	1,088,281.98

45

1

	3,615,305.57			238,448.14			3,376,857.43	
	1,269,620.49			243,272.40			1,026,348.09	
	142,683.35			25,000.00			117,683.35	
-	104,954.25			13,320.00			91,634.25	
	188,703.62			8,048.96			180,654.66	
	132,900.01			25,000.00			107,900.01	
	2,333,333.44			499,999.98			1,833,333.46	
	512,923.35			59,735.00			453,188.35	
2014	203,363.33			26,000.00			177,363.33	
2015	33,598.47			3,488.39			30,110.08	
2016 ()	84,000.00			18,000.00			66,000.00	
2016	438,581.23			36,295.00			402,286.23	
2017	800,000.00						800,000.00	
2017	716,178.30			50,000.00			666,178.30	

6.18								
2017	353,766.65			25,000.00			328,766.65	
	94,270.86			5,898.30			88,372.56	
	2,021,360.00			440,000.00			1,581,360.00	
	36,648,637.78			1,256,524.74			35,392,113.04	
2019	0.00	200,000.00					200,000.00	

52

53

		+ -					
	140,000,000.00					140,000,000.00	

54

1

2

55

	175,257,973.90			175,257,973.90
	3,012,669.67	1,102,091.50		4,114,761.17
	178,270,643.57	1,102,091.50		179,372,735.07

1,102,091.50

56**57****58****59**

	44,036,242.10			44,036,242.10
	44,036,242.10			44,036,242.10

60

		203,268,713.31	191,946,757.72
		203,268,713.31	191,946,757.72
		11,371,662.81	11,335,477.71
			-423,997.00
		214,640,376.12	203,706,232.43

1) 0

2) 0

3) 0

4) 0

5) 0

61

	173,184,308.96	62,254,387.15	214,756,756.40	44,700,869.75
	52,728.70			

	1	2			
			99,439,715.83		99,439,715.83
			61,072,011.10		61,072,011.10
			12,461,134.68	264,176.05	12,725,310.73
			172,972,861.61	264,176.05	173,237,037.66
			53,577,106.98		53,577,106.98
			63,422,471.25		63,422,471.25
			27,503,912.93		27,503,912.93
			15,189,526.74		15,189,526.74
			13,279,843.71		13,279,843.71
				264,176.05	264,176.05
			172,972,861.61	264,176.05	173,237,037.66

0.00

62

		878,480.97	1,310,656.99
		717,879.51	1,137,306.78
		4,310.09	2,422.59
		75,936.27	127,910.16
		331,267.72	407,688.27
		729,773.34	790,109.33
		3,180.00	1,800.00
		11,571.12	24,666.46
		2,752,399.02	3,802,560.58

63

	48,649,480.37	84,441,502.55
	15,043,678.85	19,828,100.02
	1,132,441.64	2,307,978.70
	0.00	1,391,738.89
	945,437.71	1,169,615.546

	3,463,452.01	1,581,189.01
	1,900,667.35	3,818,337.86
	1,912,936.87	2,149,456.09
	98,837.58	282,955.04
	12,831.18	358,843.81
		754.72
	106,386.14	637,599.57
	669,272.65	3,730,998.63
	1,202,910.71	956,478.58
	19,241,139.70	29,116,209.23

66

	4,202,766.27	3,485,240.22
	-709,425.06	-1,044,277.43
	45,627.24	19,053.58
	1,244.28	9.54
	3,540,212.73	2,460,025.91

67

-		5,000.00
-		600,000.00
-		270,000.00
-		35,000.00
-		12,000.00
-		12,000.00
-		2,000,000.00
-161		200,000.00
	2,974,030.90	2,506,531.86
		14,000.00
		1,000,000.00

-2018		24,000.00
		120,000.00
2018		10,000.00
-	28,800.00	
-2018	409,700.00	
-2020	710.00	
-	-900,000.00	
-	50,000.00	
19	48,110.65	
	8,034.10	
	3,554,300.00	
-	300,000.00	
-	49,845.93	
-	700,000.00	
-	80,000.00	
-2019	1,000.00	

68

	8,564,078.87	1,645,869.60
		3,949,788.68
	8,564,078.87	5,595,658.28

69

70

71

	2,151.62	21,594.97
	443,525.26	237,789.76
	445,676.88	259,384.73

72

		-408,097.39
		-408,097.39

73

	8,714.86	-3,108.72

74

	359,764.70	549,318.09	359,764.70
	15,642.04	70,808.68	15,642.04
	375,406.74	620,126.77	375,406.74

75

	42,917.76	17,800.00	42,917.76
	55,955.35	129,710.63	55,955.35
	19,340.45		16,140.35
	118,213.56	147,510.63	118,213.56

76

1

--	--

2

	13,115,166.38
/	1,967,274.96
	-1,338,209.05
	629,065.91

77

78

1

	2,000.00	187,422.86
	4,481,390.03	4,418,900.00
	709,425.06	444,256.50
	1,294,922.45	428,540.61
	72,299.07	1,553,627.97
	6,560,036.61	7,032,747.94

2

	85,575,659.83	120,542,402.12
	417,123.53	2,287,180.75
	906,862.75	1,183,776.11
	6,216,619.76	8,982,602.71
	93,116,265.87	132,995,961.69

3

4

5**6**

		33,722,686.20
		33,722,686.20

79**1**

--	--	--

2

3

4

	106,142,365.89	93,470,021.12
	3,110.50	2,095.50
	106,023,851.37	93,467,925.62
	115,404.02	
	106,142,365.89	93,470,021.12

80

81

	250,000.00	
	148,533,137.50	
	36,439,257.82	
82.5%	96,937,500.00	2018 12 24 82.5% 321121000182
	282,159,895.32	--

82

1

2

□

83

84

1

-	28,800.00		28,800.00
-2018	409,700.00		409,700.00
-2020	710.00		710.00
-	50,000.00		50,000.00
19	48,110.65		48,110.65
	8,034.10		8,034.10
	3,554,300.00		3,554,300.00
-	300,000.00		300,000.00
-	49,845.93		49,845.93
-	700,000.00		700,000.00
-	80,000.00		80,000.00
-2019	1,000.00		1,000.00
2019	200,000.00		

2

√

	900,000.00	

85

1

1

2

3

4

□

5

6

2

1

2

3

3

4

□

□

5

6

2019 6 11

100% 1,150

2019 6 28

2019 7

1

1

				100.00%			
				100.00%			

				100.00%		

4

5

2

1

2

3

1

				49.00%	
				50.00%	
				39.20%	

4,000

50%

5

0.0625%

3995

49.9375%

50%

2

3

	/		/	
	65,404,645.25	561,940.54	18,584,188.45	389,182.14
	8,872,435.02	64,000,000.00	8,243,653.87	48,000,000.00

	74,277,080.27	64,561,940.54	26,827,842.32	48,389,182.14
	40,803,604.54		20,677,700.32	
	9,557,376.25		31,384.61	
	50,360,980.79		20,709,084.93	
	23,916,099.48	64,561,940.54	6,118,757.39	48,389,182.14
	11,718,888.74	32,280,970.27	2,998,191.12	24,194,591.07
	24,213,888.75	40,462,138.14	15,489,784.51	24,375,758.94
	53,952,501.92	242,718.50	8,696,101.99	
	17,804,294.37	172,758.40	3,572,199.03	-104,507.92
	17,804,294.37	172,758.40	3,572,199.03	-104,507.92

4

5

6

7

8

4

5

6

2020 6 30

账龄	账面余额	减值准备
应收票据	4,698,485.18	
应收账款	42,587,725.09	3,108,702.24
其他应收款	2,212,038.40	11,709.92
合计	49,498,248.67	3,120,412.16

2020 6 30

3

项目	账面价值	未折现的合同现金流量总额	1年以内	1年以上
短期借款	133,020,000.00	135,573,139.73	135,573,139.73	
应付账款	1,028,029.02	1,028,029.02	1,028,029.02	
其他应付款	2,212,038.40	2,212,038.40	2,212,038.40	
合计	136,260,067.42	138,813,207.15	138,813,207.15	

1.

2020 6 30 13,302

2.

2020 6 30

3.

1

2

3

4

5

6

7

8

9

1

			5,000	25.05%	25.05%

2

1

3

3

4

5

1

/

		170,094.36			141,509.46

250,000.00

(

5

6

7

	3,314,962.23	3,948,060.54

8

6

1

2

		30,000.00	25,000.00
		85,874.30	0.00

7

8

1

√

	0.00
	0.00
	148,200.00

1 2018

公司本期授予的各项权益工具总额	无
公司本期行权的各项权益工具总额	无
公司本期失效的各项权益工具总额	14.82万股
公司期末发行在外的股票期权行权价格的范围和合同剩余期限	行权价格29.28元/股，第三期股票期权的有效期为2018年3月26日至2021年3月25日，合同剩余期限9个月
公司期末发行在外的其他权益工具行权价格的范围和合同剩余期限	无

1

2018 > 144 395.70 2018 29.28 2018 3 26

12 36

行权期	行权时间	业绩考核目标	解锁比例
第一个行权期	自授权日起12个月后的首个交易日起至授权日起24个月内的最后一个交易日当日止；	以2017年度营业收入为基数，2018年营业收入增长率不低于50%；	40.00%
第二个行权期	自授权日起24个月后的首个交易日起至授权日起36个月内的最后一个交易日当日止；	以2017年度营业收入为基数，2019年营业收入增长率不低于80%；	30.00%
第三个行权期	自授权日起36个月后的首个交易日起至授权日起48个月内的最后一个交易日当日止。	以2017年度营业收入为基数，2020年营业收入增长率不低于100%。	30.00%

2

2018 198.54 2018
197.16
2019 113.37 2019
83.79
14.82 2020 6 30 68.97

2 2020

公司本期授予的各项权益工具总额	无
公司本期行权的各项权益工具总额	无
公司本期失效的各项权益工具总额	无
公司期末发行在外的股票期权行权价格的范围和合同剩余期限	行权价格31.23元/股，股票期权的有效期为2020年5月12日至2023年5月11日，合同剩余期限不超过36个月
公司期末发行在外的其他权益工具行权价格的范围和合同剩余期限	无

1

2020 5 12

2020 4 30 2020 2020
2020 5 12 35 2,800,000
36

12

行权安排	行权时间	业绩考核目标	行权比例
第一个行权期	自授权日起12个月后的首个交易日起至授权日起24个月内的最后一个交易日当日止	2020年度，以下条件需全部达标： (1) 五款公司在研全球创新药均获批国内临床，且至少其中三款在研全球创新药国内 I 期临床完成首例受试者入组； (2) 2020年度主力产品四甘定（公司在售的福甘定-替诺福韦、恩甘定-恩替卡韦、贺甘定-拉米夫定和阿甘定-阿德福韦酯四大核苷（酸）类抗乙型肝炎病毒药物）总销售量相比2019年增长50%。	50.00%
第二个行权期	自授权日起24个月后的首个交易日起至授权日起36个月内的最后一个交易日当日止	2021年度，以下条件其中之一达标： (1) 至少两款公司在研全球创新药国内 II 期临床完成首例受试者入组； (2) 2021年度营业收入相比2020年增长30%。	50.00%

2

2

√

	-
	3,212,913.71
	1,102,091.50

1 2018

授权日权益工具公允价值的确定方法	布莱克-斯科尔斯期权定价模型
可行权权益工具数量的确定依据	预计可以达到行权条件，被授予对象均可行权
本期估计与上期估计有重大差异的原因	无
以权益结算的股份支付计入资本公积的累计金额	2,327,113.71
本期以权益结算的股份支付确认的费用总额	216,291.50

2 2020

授权日权益工具公允价值的确定方法	布莱克-斯科尔斯期权定价模型
可行权权益工具数量的确定依据	预计可以达到行权条件，被授予对象均可行权
本期估计与上期估计有重大差异的原因	无
以权益结算的股份支付计入资本公积的累计金额	885,800.00
本期以权益结算的股份支付确认的费用总额	885,800.00

3

□

4

5

2

3

1

2

3

4

1

1

2

2

3

1

2

4

5

6

1

2

3

4

7

8

1

1

	16,966, 461.68	100.00 %	1,151,8 31.33	6.79%	15,814, 630.35	24,824, 439.59	100.00 %	1,574,2 99.48	6.34%	23,250,1 40.11
	12,605, 759.52	74.30 %	914,68 6.56	7.26%	11,691, 072.96	17,934, 418.81	72.25%	918,63 9.69	5.12%	17,015,7 79.12
	4,360,7 02.17	25.70								

账龄		期末余额		
计提比例 (%)			账面余额	坏账准备
54.62	5.00	1年以内(含1年)	4,141,092.31	207.0
79.97	8.00	1至2年	205,999.67	16.4
-	15.00	2至3年	-	
0.00	30.00	3至4年	0.01	
-	60.00	4至5年	-	
10.18	100.00	5年以上	13,610.18	13.6
144.77	5.44	合计	4,360,702.17	237.

1	1	16,271,381.94
1	2	323,526.15
2	3	31,765.00
3		339,788.59
3	4	25,412.01
4	5	0.00
5		314,376.58
		16,966,461.68

2

	918,639.69		3,953.13		914,686.56
	655,659.79		418,515.02		237,144.77
	1,574,299.48		422,468.15		1,151,831.33

3

4

	1,474,304.52	8.69%	73,715.23
	1,169,802.00	6.89%	58,490.10

	1,128,930.00	6.65%	56,446.50
	898,046.00	5.29%	44,902.30
	805,195.18	4.75%	40,259.76
	5,476,277.70	32.27%	

5

6

2

	1,813,193.28	

	169,940.72	221,071.98
	1,821,690.32	724,176.26

2)

	12	()	()	
2020 1 1	11,061.51			11,061.51
2020 1 1	—	—	—	—
	2,564.47			2,564.47
2020 6 30	8,497.04			8,497.04

□

1 1		1,455,417.32
1		

4)

5)

		1,000,000.00	1	54.89%	
		313,245.00	2 3	17.20%	
		72,722.62	1	3.99%	
		50,000.00	1	2.74%	
		50,000.00	1	2.74%	
	--	1,485,967.62	--	81.57%	

6)

7)

8)

3

	188,177,500.00		188,177,500.00	185,177,500.00		185,177,500.00
	66,781,622.32		66,781,622.32	39,865,543.45		39,865,543.45
	254,959,122.32	0.00	254,959,122.32	225,043,043.45	0.00	225,043,043.45

1

	()					()	
	15,000,000.00					15,000,000.00	
	44,500,000.00					44,500,000.00	
	28,540,000.00	3,000,000.00				31,540,000.00	

	200,000.00					200,000.00	
	96,937,500.00					96,937,500.00	
	185,177,500.00	3,000,000.00				188,177,500.00	

2

	((
))	

	1	2			
			99,439,715.83		99,439,715.83
			619,469.04	5,718.86	625,187.90
			100,059,184.87	5,718.86	100,064,903.73
			25,596,324.60		25,596,324.60
			34,624,969.33		34,624,969.33
			19,194,511.98		19,194,511.98
			12,143,878.74		12,143,878.74
			7,880,031.18		7,880,031.18
			619,469.04	5,718.86	625,187.90
			100,059,184.87	5,718.86	100,064,903.73

0.00 0 0.00 0 0.00 0.00 0

5

	8,564,078.87	1,645,869.60
		-6,700,000.00
	8,564,078.87	-5,054,130.40

6

1

√

	8,714.86	
	7,304,531.58	

	260,393.28	
	2,283,078.44	
	1,484,475.82	
	481,523.99	
	7,890,718.35	--

1

1

‘ (AF) VĨNH

2 F(

		/	/
	1.99%	0.0812	0.0812

